Brief: Doma Perpetual Urges Pacira Biosciences Shareholders To Judge Sale Price Adequacy
21/05/2026 19:05
May 21 (Reuters) - Doma Perpetual: DOMA PERPETUAL - PACIRA BIOSCIENCES SHAREHOLDERS SHOULD DECIDE IF SALE PRICE THE CO FINDS THROUGH DISCIPLINED, BOARD‑SUPERVISED PROCESS IS ADEQUATE IN BEST INTERESTS Further company coverage: PCRX.O ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Pacira BioSciences
See all newsUS STOCKS ON THE MOVE-Palantir, Haemonetics
U.S. STOCKS ON THE MOVE-Palantir, Haemonetics, Starbucks
Pacira BioSciences jumps on $1.65 billion Viatris buyout deal
Brief: Viatris - Pacira To Pay Viatris $62 Million Termination Fee Under Specified Circumstances
Pacira BioSciences jumps on $1.65 billion Viatris buyout deal